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ounis hypersensitivity coronary syndrome is associated with
resence of older thrombus in patients with late and very late
rug-eluting stent thrombosis
Nishihira et al. [1] found that in most patients with late and very
ate drug-eluting stent thrombosis, the creation of thrombus is not
n acute event but starts at least days to weeks before culminat-
ng in an acute event. The authors concluded that their ﬁndings
rovide further information about another potential mechanism
f drug-eluting stent thrombosis. However, they have not referred
o hypersensitivity coronary syndrome and they have not stained
he aspirated thrombus for eosinophilic inﬁltration. We  strongly
elieve that stent thrombosis and late stent thrombosis are, mainly,
anifestations of the Kounis hypersensitivity associated coronary
yndrome [2] caused by an “antigenic complex” of nickel alloys,
olymers, eluted drugs, and possibly concominant oral antiplatelet
rugs and environmental exposures. So far, all animal studies and
xperiments, reported pathology ﬁndings, and clinical reports in
ll patients who have died from stent thrombosis, point toward
 hypersensitivity inﬂammation with inﬁltration of various inter-
elated and interacting inﬂammatory cells including eosinophils,
acrophages, T-cells, and mast cells. Eosinophils are bone marrow-
erived granulocytic leukocytes, which normally reside in tissues
nd express H4 histamine receptors. These receptors facilitate
osinophil chemotaxis toward mast cells, which are the major pro-
ucers of histamine. Both eosinophils and mast cells are important
ffector cells in the late phase allergic response and they have been
mplicated in the pathogenesis of allergic diseases. Eosinophils
espond to histamine by changing cell shape, upregulation of adhe-
ion molecules, and chemotaxis, and these responses are mediated
y the H4 receptor expressed on eosinophils.
Hypersensitivity inﬂammation goes through three phases [3],
he early phase which lasts minutes, the late phase which lasts from
 h to 2 days, and the chronic phase which follows a continuous,
ersistent, and repetitive allergen exposure and lasts as long as the
llergen is present. It seems likely that early, late, and very late stent
hrombosis correspond temporally with the early, late, and chronic
llergic inﬂammation independently of level of documentation as
eﬁnite or conﬁrmed, probable and possible. Indeed, the ﬁndings
f Nishihira et al. [1] are compatible and may  temporally corre-
pond with the early, late, and chronic phases of hypersensitivity
nﬂammatory process. The newer stents bearing the misleading
erm cobalt–chromium or platinum–chromium stents and eluting
he sirolimus analogues everolimus and zotarolimus both contain
ickel and other metals. Nickel hypersensitivity is a ubiquitous phe-
omenon and may  reach the level of 24.6% [4].  Human platelets
re activated through receptors for multiple agonists but a sub-
et of platelets contains FCRI and FCRII IgE receptors [5] which
ould be activated by corresponding antigens. Everolimus stents
ontain about 10% nickel and zotarolimus stents contain 35% nickel
nd despite the stent electropolishing and polymer coverage still
elease nickel ions locally and in systemic circulation.
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ttp://dx.doi.org/10.1016/j.jjcc.2012.05.001There are some unexpected, bizarre, strange, astonishing, and
surprising reports according to which patients with stent implan-
tation develop allergic reactions elsewhere from other causes and
contemporarily develop intrastent thrombosis. For example, aller-
gic reactions from propyphenazone, contrast material, and insect
sting were accompanied by intrastent thrombosis denoting that
stents such as magnets attract inﬂammatory cells and constitute
the area of possible mast cell and platelet activation [5].
In order to predict and prevent hypersensitivity associated stent
thrombosis, in general, it has been recommended that several
measures should be taken before and after stent insertion. Fortu-
nately some of these recommendations have been incorporated in
the current protocols [5].  Furthermore, manufacturing companies
have issued, nowadays, ofﬁcial warnings and information sheets,
especially for the new generation of stents, emphasizing the con-
traindications for their implantation which include, mainly, any
history of hypersensitivity to any of the stents’ components and
to drugs the stented patients will take after their discharge from
hospital. We  are wondering how many of us have noticed these
manufacturers’ recommendations.
Therefore, the solution seems to be in sight: antigen-free stent
implantation in order to avoid catastrophic late and very late drug-
eluting stent thrombosis.
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